

# Chemical fingerprint analysis for quality control of *Fructus Aurantii Immaturus* based on HPLC-DAD combined with chemometric methods

Xiaona Xu,<sup>ab</sup> Junhui Jiang,<sup>b</sup> Yizeng Liang,<sup>\*a</sup> Lunzhao Yi<sup>a</sup> and Jinle Cheng<sup>c</sup>

Received 20th July 2010, Accepted 23rd September 2010

DOI: 10.1039/c0ay00455c

High-performance liquid chromatographic (HPLC) fingerprints of 12 authentic samples and 26 commercial samples of *Fructus Aurantii Immaturus* (FAI) from different sources of China were measured. Firstly, the main bioactive compounds in citrus herb, namely naringin and hesperidin, were identified and quantitated. Then, principal components analysis (PCA) was performed to differentiate and classify the studied samples based on the principal peaks and entire chromatograms, respectively. Hierarchical clustering analysis (HCA) and similarity analysis (SA) were further conducted to validate the clustering results. The optimized HPLC-DAD method aided by forementioned chemometric methods shows that the chemical fingerprints of 38 samples from extensive sources could be reasonably identified and systematically analyzed, which offers a new clue for the study of traditional Chinese medicines (TCM). The results obtained will provide a useful foundation for quality control of herbal medicine.

## 1 Introduction

*Fructus Aurantii Immaturus* (FAI) is an effective traditional Chinese medicine (TCM) used for more than 2000 years in the treatment of dissipating stagnant qi, removing qi stagnation, eliminating sputum and dispersing painful abdominal mass. It is the dried, unripe fruit of *Citrus aurantium L.*, cultivated variety or *citrus sinensis Osbeck* of *Rutaceae*, often called Zhishi in Chinese and officially listed in the Chinese Pharmacopoeia.<sup>1</sup> Flavonoids, alkaloids and essential oil components are the major bioactive compositions in this herb. Hesperidin and naringin, the important representative flavonoids in citrus herb, possess antioxidant, anti-inflammatory and anti-ulcer properties as most flavonoids do.<sup>2–4</sup>

It is well known that traditional Chinese medicines (TCMs) contain multiple chemical components, each of which may be relevant to the medicine's putative activity. The various origins, different processing procedures, saving conditions and deposited year may lead to the difference in the contents of chemical constituents and compound denominations of herbal medicine, which may directly influence therapeutic effects. Therefore, discrimination of an herbal material's origin as well as determination of its bioactive ingredients is crucial in order to ensure its authenticity, quality, safety and efficacy. Until now, besides macroscopic and microscopic authentication, chemical identification of herbal materials with various pattern recognition methods, such as similarity analysis (SA), hierarchical clustering analysis (HCA) and principal component analysis (PCA), is

increasingly employed to discriminate the habitats of raw herbal materials.<sup>5–12</sup>

Publications about FAI are mostly about one or several compounds' qualification and quantification in HPLC-UV, HPLC-UV-MS and HPLC-MS-MS, mainly hesperidin, naringin and synephrine.<sup>13–18</sup> Although there are some publications associated with the fingerprints of FAI, none of them involved systemic comparison among different herbal origins, identification using characteristic chemical compounds or a discrimination model. In the present study, a HPLC fingerprint method in combination with chemometric methods to analyze FAI from various origins was described. To begin with, the main bioactive compounds in citrus herb, namely naringin and hesperidin, were identified and quantitated. Then, principal components analysis (PCA) was performed to differentiate and classify the studied samples based on the principal peaks and entire chromatograms, respectively. Then, hierarchical clustering analysis (HCA) and similarity analysis (SA) were further conducted to validate the clustering results adjunctively. Finally, the HPLC fingerprints of 38 samples from extensive sources were roundly analyzed and identified. This investigation shows that the developed methodology can be generalized in the research of quality control of herb medicines. The results obtained may also provide a useful chemical basis for future research of this herb.

## 2 Experimental

### 2.1 Chemicals and reagents

The standards of hesperidin (batch number 0721-9909) and naringin (batch number 0722-9805) were purchased from National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). Their chemical structures are shown in Fig. 1. HPLC grade methanol, acetonitrile and polyphosphoric acid were purchased from Jiangsu Hanbon Science and Technology Co., Ltd (Huaian, Jiangsu Province, China). Other reagents were of analytical grade. Water was deionized in

<sup>a</sup>College of Chemistry and Chemical Engineering, Research Center of Modernization of Chinese Medicines, Central South University, 410083 Changsha, Hunan, People's Republic of China. E-mail: yizeng\_liang@263.net; Fax: +86-731-8825637

<sup>b</sup>College of Chemistry and Chemical Engineering, University of South China, 421001 Hengyang, Hunan, People's Republic of China

<sup>c</sup>Zhongzhi pharmaceutical limited company, 528415 Zhongshan, Guangdong, People's Republic of China



**Table 1** Collection information of the studied samples

Sample no.	Sources	Habitat	Production time
01	Purchased from Xian, Shanxi	Jiangxi	2008
02	Purchased from Jinxiang Drug Store, Beijing	unknown	2008
03	Purchased from Zhonglian Drug Store, Wuhan, Hubei	Jiangxi	2009
04	Purchased from Hefei, Anhui	unknown	2009
05	Purchased from Shengyuan Drug Store, Nanning, Guangxi	Hunan	2008
06	Purchased from Changchun, Jilin	Hunan	2009
07	Purchased from Hengkang pharmaceutical company, Yiyang, Hunan	unknown	unknown
08	Hunan (authentic sample)	Hunan	2009
09	Hunan (authentic sample)	Hunan	2009
10	Purchased from, Yunnan	Yunnan	2009
11	Purchased from Dongbei Drug Store, Shenyang, Liaoning	Hunan	2009
12	Purchased from Taiyuan, Shanxi	Unknown	2008
13	Xinyu, Jiangxi (authentic sample)	Jiangxi	2009
14	Xinyu, Jiangxi (authentic sample)	Jiangxi	2009
15	Purchased from Guilin, Guangxi	Hunan	2008
16	Purchased from Haikou, Hainan	Unknown	2008
17	Purchased from Harbin, Heilongjiang	Unknown	2008
18	Purchased from Kangtai Drug Store, Hengyang, Hunan	Unknown	2009
19	Qingjiang, Jiangxi (authentic sample)	Jiangxi	2009
20	Qingjiang, Jiangxi (authentic sample)	Jiangxi	2009
21	Purchased from Huaihua, Hunan	Hunan	2008
22	Purchased from Zhuji, Zhejiang	Unknown	2008
23	Purchased from Xining, Qinghai	Unknown	2009
24	Purchased from Xinjiang	unknown	2008
25	Deyang, Sichuan (authentic sample)	Sichuan	2009
26	Deyang, Sichuan (authentic sample)	Sichuan	2009
27	Purchased from Xian, Shanxi	Jiangxi	2008
28	Purchased from Linxin, Shandong	Jiangxi	2009
29	Purchased from Chenzhou, Hunan	unknown	2009
30	Purchased from Chenzhou, Hunan	unknown	2008
31	Purchased from Dongguan, Guangdong	Hunan	2008
32	Purchased from Kunming City zhongyiyuan, Yunnan	Unknown	Unknown
33	Purchased from Yiyang, Hunan	Hunan	2008
34	Panxi, Yunnan (authentic sample)	Yunnan	2009
35	Panxi, Yunnan (authentic sample)	Yunnan	2009
36	Purchased from Lanzhou, Gansu	Unknown	2009
37	Yiyang, Hunan (authentic sample)	Hunan	2008
38	Yiyang, Hunan (authentic sample)	Hunan	2008

**Table 2** The gradient elution program

Gradient/min	A (CH <sub>3</sub> CN)%	B (CH <sub>3</sub> OH)%	C (0.05% H <sub>3</sub> PO <sub>4</sub> -H <sub>2</sub> O)%
0	6.0	3.0	91.0
10	16.0	13.0	71.0
30	16.0	13.0	71.0
35	18.0	18.0	64.0
45	25.0	35.0	40.0
70	25.0	70.0	5.0
80	25.0	70.0	5.0

ultrasound, were carried out. The results demonstrated that the optimum solvent was found to be anhydrous methanol, and ultrasound was validated as the optimal extraction method, both of which enabled less interfering peaks, and provided the biggest peak area of the principal peaks and peak number.

A method involving three-factor-three-level orthogonal array design (OAD) including the components of volume of methanol (5, 15, and 25 mL), times of ultrasound (one, two and three times) and duration of extraction (10, 30, and 60 min) was developed for the optimization of the extraction. The results demonstrated that the established extraction method was adequate and appropriate for the analysis (see Table 3).

The optimization of the chromatographic conditions was performed by using the sample solution. The investigated compounds were tested and compared by using different analytical columns (*Phenomenex LUNA C18*, *Agilent XDB-C8* or *Sepax C18*) with different mobile phases (acetonitrile–water, methanol–water, and acetonitrile–methanol–water) and different gradient elution programs. The results showed that *Sepax C18* column with gradient elution of acetonitrile–methanol–water could efficiently separate the investigated markers. Considering the presence of flavonoids in the herbal extraction, 0.05% phosphoric acid was added to the mobile phase to reduce the ionization and lower the polarity of these compounds. According to the UV spectra recorded by DAD from 200 to 400 nm, 284 nm was finally chosen to achieve chromatographic fingerprint profiles and detection wavelength based on the peak area of principal peaks and peak number. The representative HPLC-DAD chromatograms of mixed standards and the extract of FAI are shown in Fig. 2.


### 3.2 Validation of the HPLC method

Each calibration curve was performed with six different concentrations of chemical markers. The square of all the correlation coefficients ( $r^2$ ) of these calibration curves were higher than 0.999. The limits of detection (LOD) and quantification (LOQ) were determined at a signal-to-noise ratio (S/N) of

**Table 3** Result of orthogonal array design assay (OA<sub>9</sub>(3<sup>3</sup>)) for extracts<sup>a</sup>

No.	Factors			Total extraction rate (%)
	A	B	C	
1	1 (1)	1 (10)	1 (10)	13.63
2	1	2 (30)	2 (30)	16.52
3	1	3 (60)	3 (50)	17.11
4	2 (2)	1	2	17.88
5	2	2	3	17.58
6	2	3	1	17.15
7	3 (3)	1	3	19.87
8	3	2	1	17.04
9	3	3	2	17.01
$K_1^b$	47.26	51.10	47.82	
$K_2$	48.61	51.14	51.41	
$K_3$	53.92	51.27	54.56	
$R^c$	7.16	0.17	6.74	

<sup>a</sup> A: Extraction number; B: Extraction time (min); C: Ratio of liquid to solid. <sup>b</sup>  $K_i = \sum$ total extraction rate at  $A_i$ ; the sum of the total extraction rates for a certain factor at each level. <sup>c</sup> R is the extreme difference of  $K_i$  ( $i = 1, 2, 3$ ) for a certain factor.



**Fig. 2** Representative HPLC-DAD chromatograms of mixed standards and the extract of *Fructus Aurantii Immaturus* (sample no. 32 in Table 1). Peak 2 and 3 are naringin and hesperidin, respectively. Peaks 1, 4 and 5 are also flavonoids compounds according to the similarities of their UV spectra with the standards naringin and hesperidin, they displaying the characteristic UV maximum absorbance of flavonoids. For terseness, the identification courses of the three peaks forementioned are omitted in this paper.

3 and 10, respectively. The data were summarized in Table 4. Precision (inter-day and intra-day), repeatability, stability and recovery were all carried out to validate the HPLC method, following some reports on determination analysis.<sup>36–38</sup>

### 3.3 Sample analysis

The established analytical method was applied to determine the contents of naringin and hesperidin in the 38 samples, which are the main bioactive ingredients in citrus herb. Identification of the compounds forementioned of the tested samples was based on comparing their UV spectra and their retention time with those of the standards. The contents of naringin and hesperidin in the tested samples were listed in Table 5. The measurable concentration ranges of the two components were in 0.143–6.267 and 1.355–9.456 mg g<sup>-1</sup>, which demonstrated the striking concentration disparity of naringin and hesperidin in herbal materials. The highest contents of the two bioactive compounds are more



**Table 4** The regression equations and detection limits for hesperidin and naringin

Compound	Regression equation	Correlation coefficient	Linear range/ $\mu\text{g mL}^{-1}$	LOD/ $\mu\text{g mL}^{-1}$	LOQ/ $\mu\text{g mL}^{-1}$
hesperidin	$Y = 5.048 \times 10^4 X - 175.3$	0.9992	2–300	0.05	0.16
naringin	$Y = 5.207 \times 10^4 X - 128.1$	0.9995	2–256	0.06	0.19

than five times the lower ones, respectively. Even in some samples naringin had not been detected or existed with very small contents so that it could not be accurately quantitated. Such consequences were in line with the Ref. 39. Flavonoids are the major effective ingredients in citrus herb, of which naringin and hesperidin are of conclusive therapeutic effect.<sup>40–42</sup> Therefore, the quantitation standards of the two compounds above-mentioned should be instituted by correlative institutions as soon as possible, which will be a great assistance to quality control of this herb. Further studies are required to find out the influence of the

compounds' concentration diversity of TCM on the therapeutic effect.

### 3.4 Principal component analysis (PCA)


**3.4.1 PCA of samples based on principal peaks.** To survey the distribution of the 38 samples, PCA was utilized to analyze and classify those HPLC-DAD data. The scores plot of PC1 versus PC2 was examined. First, the 2D-projection plot of PCA based on the five principal peaks (marked in Fig. 2) is shown in Fig. 3. Except sample no. 30, all the rest ones apparently form into two groups. The authentic samples (No. 13, 14, 19 and 20) from Jiangxi are clustered into group I as well as the commercial ones (No. 01–04, 12, 22, 27–29), and authentic samples nos. 08, 09, 37, 38 from Hunan cluster into group II including the authentic ones No. 25 and 26 from Sichuan, 34 and 35 from Yunnan, and the residuary commercial ones. The samples studied visibly clustered into groups based on the centers of Jiangxi's and Hunan's ones respectively. Obviously, No. 30 is detected as an outlier, which is a questionable sample. Herbal medicine from different origins have different chemical properties, thus different clusters come into being. Using the main peaks of fingerprints to do PCA can basically discriminate the sources of herbal materials.

**3.4.2 PCA of samples based on entire chromatograms.** In order to investigate the influence of other peaks on cluster and validate the grouping results forementioned, entire chromatograms of the 38 samples are further employed to do PCA (see

**Table 5** The contents of naringin and hesperidin in the studied samples ( $n = 3$ )<sup>a</sup>

Sample no.	Contents/ $\text{mg g}^{-1} \pm \text{S.D.}$	
	Naringin	Hesperidin
01	3.335 $\pm$ 0.011	6.176 $\pm$ 0.022
02	2.920 $\pm$ 0.003	5.317 $\pm$ 0.015
03	4.828 $\pm$ 0.007	1.355 $\pm$ 0.001
04	2.836 $\pm$ 0.005	1.526 $\pm$ 0.002
05	0.160 $\pm$ 0.001	7.060 $\pm$ 0.002
06	trace	7.907 $\pm$ 0.028
07	2.781 $\pm$ 0.004	4.693 $\pm$ 0.009
08	0.210 $\pm$ 0.001	8.198 $\pm$ 0.017
09	0.299 $\pm$ 0.001	7.873 $\pm$ 0.024
10	trace	6.632 $\pm$ 0.015
11	0.271 $\pm$ 0.002	8.686 $\pm$ 0.051
12	3.667 $\pm$ 0.017	2.062 $\pm$ 0.002
13	5.851 $\pm$ 0.021	1.526 $\pm$ 0.002
14	4.718 $\pm$ 0.004	1.840 $\pm$ 0.003
15	trace	6.946 $\pm$ 0.007
16	0.143 $\pm$ 0.000	5.577 $\pm$ 0.006
17	trace	2.867 $\pm$ 0.005
18	0.340 $\pm$ 0.001	6.062 $\pm$ 0.006
19	5.935 $\pm$ 0.001	2.468 $\pm$ 0.002
20	6.267 $\pm$ 0.006	1.549 $\pm$ 0.007
21	0.165 $\pm$ 0.000	7.973 $\pm$ 0.006
22	2.693 $\pm$ 0.003	2.627 $\pm$ 0.002
23	0.149 $\pm$ 0.000	9.456 $\pm$ 0.010
24	trace	7.000 $\pm$ 0.006
25	0.160 $\pm$ 0.000	7.060 $\pm$ 0.004
26	0.487 $\pm$ 0.001	6.886 $\pm$ 0.010
27	4.717 $\pm$ 0.005	5.634 $\pm$ 0.009
28	3.075 $\pm$ 0.002	4.966 $\pm$ 0.005
29	3.324 $\pm$ 0.001	3.637 $\pm$ 0.003
30	3.704 $\pm$ 0.002	2.624 $\pm$ 0.001
31	trace	6.436 $\pm$ 0.003
32	0.951 $\pm$ 0.000	4.667 $\pm$ 0.002
33	0.277 $\pm$ 0.001	6.658 $\pm$ 0.013
34	trace	7.427 $\pm$ 0.008
35	trace	6.547 $\pm$ 0.007
36	0.697 $\pm$ 0.005	7.685 $\pm$ 0.009
37	0.264 $\pm$ 0.001	7.300 $\pm$ 0.007
38	0.215 $\pm$ 0.000	7.060 $\pm$ 0.06

<sup>a</sup> Sample no. corresponds to Table 1.

**Fig. 3** PCA projection plot for the 38 samples, using peak areas of 5 principally common components as input data (peaks 1–5 in Fig. 2).




Fig. 4 The scatter plot obtained by PCA of the tested samples based on entire chromatograms.

Fig. 4). The results obtained demonstrate that most samples are kept in the similar clustering state comparison to the sorting results based on the five principal peaks above mentioned. However, sample no. 32 is shown to be an outlier together with No. 30. It appears that when employing PCA to cluster herbal materials, the input data with entire chromatograms are better than that of several principal peaks, which exhibits stronger ability to display the chemical characters of samples.

All programs of PCA were coded in MATLAB 6.5 for windows.

### 3.5 Hierarchical clustering analysis (HCA)

In order to judge the reliability of the categorization results of PCA forementioned and compare them with those of other

classification methods, HCA was utilized to classify those 38 fingerprints. Centroid Euclidean distance was selected as a measurement. The hierarchical clustering was done by Traditional Chinese medicine quality control system/extendable data base, which was developed by our laboratory. A dendrogram was generated (see Fig. 5), which revealed the relationships among the studied samples. Generally, the thirty-eight chromatograms were divided into two basal clusters. The authentic samples (No. 13, 14, 19 and 20) from Jiangxi together with sample nos. 1–4, 7, 12, 22 and 27–30 were in group I and the other samples including the authentic samples from Hunan were in group II, which was again divided into subgroups, respectively. Sample nos. 1–4, 7, 12–14, 19, 20, 22, and 27–29 were in subgroup A, 30 and 32 was in subgroup B and D respectively, and the rest ones centered by the authentic samples from Hunan,




Fig. 5 The result of hierarchic clustering analysis.

Sichuan and Yunnan, were in subgroup C. The results of HCA indicated that samples which had similar chemical profiles were divided into one group. Here, sample nos. 30 and 32 are again discriminated as singular points. The result of HCA is similar with that of PCA based on entire chromatograms, and further confirms the latter. Both of them were based on entire fingerprints when classification done. It is obvious that overall fingerprints have larger abilities to reveal the variability of the tested samples than partial principal peaks when conducting discrimination analysis.

### 3.6 Similarity analysis of HPLC fingerprints

Based on the definition of the fingerprint of TCM, a chromatographic fingerprint is actually a chromatographic pattern of some common kinds of pharmacologically active and chemically characteristic components in the TCM. "Integrity" and "fuzziness" are two fundamental attributes of fingerprints of TCMs. With the help of chromatographic fingerprints, the authentication and identification of herbal medicines can be conducted, even if the quantity of the chemically characteristic constituents are not exactly the same among different samples. The chromatographic fingerprints reveal both the "sameness" and "differences" between various samples successfully. In this study, the 38 samples from different origins in China were analyzed under the optimum chromatographic conditions.

Similarity analysis is a conventional method describing the similarity and dissimilarity among the fingerprints quantitatively. Here, similarity analysis was carried out on the 38 fingerprints by a Traditional Chinese medicine quality control system/extendable database developed by our laboratory. The correlation coefficient of similarity between each chromatographic profile of FAI samples and the simulative median chromatogram was calculated and generated, respectively (see Table 6). According to the results of Table 6, taking 0.90 as an appropriate threshold, the samples with the correlation coefficients above it will be clustered to a group, and those below it will be sorted to another group, which has been properly proved by the previous cluster results from PCA and HCA.

In order to see the details in the fingerprints, the median chromatograms of the two groups of FAI together with the two outliers are shown in Fig. 6. Peaks that existed in all chromatograms are considered as "common peaks", indicating the sameness among various samples. 18 peaks coexisting in the 38 samples are indicated for visual comparison of the tested samples. Among the common components, the contents of hesperidin and narirutin are relatively high and stable, which were in correspondence with the literatures reported.<sup>11–13</sup> Peak M and N existing in Fig. 6 (1) are not found in Fig. 6 (2), while peak P emerging in Fig. 6 (2) does not exist in Fig. 6 (1). Furthermore, there are many tiny peaks in Samples no. 30 and 32 with the retention time range 40–70 min (see Fig. 6 (3) and Fig. 6 (4)). The non-common peaks in each chromatogram represent the fuzziness among the same kind of TCM along with the different contents of the same component existing in the samples examined. It is in accordance with the theory that the secondary metabolites of plant herbs would clearly vary in different locations. Chinese medicine theory emphasizes synergism of multiple components to enhance remedy, lower toxicity and prevent side

**Table 6** The similarities of the studied samples


Sample <sup>a</sup>	Similarities <sup>b</sup>
01	0.522
02	0.707
03	0.182
04	0.223
05	0.979
06	0.984
07	0.505
08	0.996
09	0.998
10	0.993
11	0.995
12	0.274
13	0.199
14	0.264
15	0.992
16	0.994
17	0.964
18	0.998
19	0.180
20	0.181
21	0.994
22	0.384
23	0.989
24	0.990
25	0.997
26	0.998
27	0.483
28	0.539
29	0.420
30	0.537
31	0.994
32	0.954
33	0.994
34	0.990
35	0.992
36	0.993
37	0.997
38	0.995

<sup>a</sup> The sample number from 01 to 38 are corresponding to the serial numbers as listed in Table 1. <sup>b</sup> The correlation coefficient was calculated based on the information obtained from the median of all chromatograms.

effects. Different constituents synergistically interact together and generate different curative effects. Further work should be probed on the variance of pharmacodynamic action of FAI from different origins.

## 4 Conclusions

The developed chromatographic method had been employed to identify and determine the two effective components, say narigin and hesperidin. With the help of chemometric methods, say PCA, HCA and SA, the 38 herbal samples of FAI from various sources can be accurately differentiated. The method developed in this paper has demonstrated that it is able to discriminate between different herbal origins, detect the content of bioactive ingredients and systematically analyze traditional Chinese medicines, which offers a new clue for the study of traditional Chinese medicine. The results obtained will be helpful for quality control, rational herbal usage and pharmacodynamic research of herbal medicine.



**Fig. 6** Mean chromatograms of (1) 4 authentic samples including four from Jiangxi (sample no. 12, 13, 19 and 20) and 10 commercial samples (sample no. 1–4, 7, 14, 22, 27–29); (2) 6 authentic samples including four from Hunan (sample no. 08, 09, 37 and 38) and 2 from Sichuan (sample no. 34 and 35), and 2 from Yunnan (sample no. 25 and 26), and 16 commercial samples. (3) and (4) are the chromatograms of sample no. 30 and 32 (commercial samples), respectively. The sample numbers were coincident in Table 1. The five peaks 6–9 and 11 are corresponding to peaks 1–5 in Fig. 2, respectively. The other compounds cannot be identified.

## Acknowledgements

The authors gratefully acknowledge the financial support from the International Co-operative Project of Science and Technology from the Ministry of Science and Technology of People's Republic of China (contract/grant number: 2007DFA40680), National Nature Foundation Committee of P.R. China (Grant No. 20875104 and 21075138), China Postdoctoral Science Foundation funded project (No. 20080440181), Special Foundation of China Postdoctoral Science (No. 200902481) and Central South University Science Development Foundation (No. 10SDF22).

## References

- Chinese Pharmacopoeia Committee. *Chinese Pharmacopoeia [M]*. Publishing house of chemical industry, Beijing, 2005, pp. 118–119.
- Y. T. Chen, R. L. Zheng, Z. J. Jia and Y. Ju, *Free Radical Biol. Med.*, 1990, **9**, 19–21.
- S. V. Jovanovic, S. Steenken, M. Tosic, S. Steenken, B. Marjanovic and M. G. Simic, *J. Am. Chem. Soc.*, 1994, **116**, 4846–4851.
- M. J. Martín, E. Marhuenda, C. Pérez-Guerrero and J. M. Franco, *Pharmacology*, 1994, **49**, 144–150.
- P. Zou, Y. Hong and H. L. Koh, *J. Pharm. Biomed. Anal.*, 2005, **38**, 514–520.
- L. F. Hu, S. P. Li, H. Cao, J. J. Liu, J. L. Gao, F. Q. Yang and Y. T. Wang, *J. Pharm. Biomed. Anal.*, 2006, **42**, 200–206.
- B. Y. Li, Y. Hu, Y. Z. Liang, P. S. Xie and Y. Ozaki, *Analyst*, 2006, **131**, 538–546.
- K. Y. L. Yap, S. Y. Chan and C. S. Lim, *Food Res. Int.*, 2007, **40**, 643–652.
- Y. Zhao, Z. W. Li, X. Zhou, Z. W. Cai, X. J. Gong and C. Y. Zhou, *J. Pharm. Biomed. Anal.*, 2008, **48**, 1230–1236.
- W. J. Kong, Y. L. Zhao, X. H. Xiao, C. Jin and Z. L. Li, *Phytomedicine*, 2009, **16**, 950–959.
- Y. Y. Zhao, Y. M. Zhang, R. C. Lin and W. J. Sun, *Fitoterapia*, 2009, **80**, 333–338.
- L. Z. Yi, D. L. Yuan, Y. Z. Liang, P. S. Xie and Y. Zhao, *Anal. Chim. Acta*, 2009, **649**, 43–51.
- P. Mouly, E. M. Gaydou and A. Auffracy, *J. Chromatogr., A*, 1998, **800**, 171–179.
- L. Ding, X. B. Luo, F. Tang, J. B. Yuan, Q. Liu and S. Z. Yao, *J. Chromatogr., B: Anal. Technol. Biomed. Life Sci.*, 2007, **857**, 202–209.
- X. M. Qin, Y. T. Dai, L. Z. Zhang, X. Q. Guo and H. X. Shao, *Phytochem. Anal.*, 2009, **20**, 307–313.
- Y. Lu, C. Zhang, P. Bucheli and D. Wei, *Plant Foods Hum. Nutr.*, 2006, **61**, 57–65.



- 17 C. Wand, Y. J. Pan, G. R. Fan, Y. F. Chai and Y. T. Wu, *Biomed. Chromatogr.*, 2010, **24**, 235–244.
- 18 Q. Wang and Y. Dan, *Heilongjiang Med. J.*, 2008, **21**, 1–3.
- 19 T. Layloff, *Pharm. Technol.*, 1991, **15**, 146–148.
- 20 WHO, *Guidelines for the assessment of herbal medicine*. WHO: Geneva, 1996.
- 21 Drug Administration Bureau of China, *Requirements for studying fingerprint of traditional Chinese medicine injection*, Beijing, 2002.
- 22 W. J. Welsh, W. K. Lin, S. H. Tersigni, E. Collantes, R. Duta and M. S. Carey, *Anal. Chem.*, 1996, **68**, 3473–3482.
- 23 E. R. Collantes, R. Duta, W. J. Welsh and W. L. Zielinski, *Anal. Chem.*, 1997, **69**, 1392–1397.
- 24 T. I. Aksenova, I. V. Tetko, A. G. Ivakhnenko, A. E. P. Villa, W. J. Welsh and W. L. Zielinski, *Anal. Chem.*, 1999, **71**, 2423–2430.
- 25 L. B. A. Hansen, *J. Pharm. Sci.*, 2001, **90**, 943–948.
- 26 Y. Y. Cheng, M. J. Chen and W. D. Tong, *J. Chem. Inf. Comput. Sci.*, 2003, **43**, 1068–1076.
- 27 Y. Y. Cheng, M. J. Chen and W. J. Welsh, *J. Chem. Inf. Comput. Sci.*, 2003, **43**, 1959–1965.
- 28 L. J. Ni, P. Li, R. Zheng, L. G. Zhang and L. Z. Zhu, *Chin. Trad. Pat. Med.*, 2002, **24**, 79–82.
- 29 M. J. Chen, Y. Y. Cheng and R. C. Lin, *Chin. Trad. Pat. Med.*, 2002, **24**, 905–908.
- 30 X. Wang, W. Y. Wang, K. R. Zhang and K. S. Bi, *J. Shenyang Pharm. Univ.*, 2003, **20**, 360–363.
- 31 Y. P. Li, Z. Hu and L. C. He, *J. Pharm. Biomed. Anal.*, 2007, **43**, 1667–1672.
- 32 P. Zou, Y. Hong and H. L. Koh, *J. Pharm. Biomed. Anal.*, 2005, **38**, 514–520.
- 33 R. M. Yu, B. Ye, C. Y. Yan, L. Y. Song, Z. Zhang, W. Yang and Y. Zhao, *J. Pharm. Biomed. Anal.*, 2007, **44**, 818–823.
- 34 W. Li, Y. L. Deng, R. J. Dai, Y. H. Yu, M. K. Saeed, L. Li, W. W. Meng and X. S. Zhang, *J. Pharm. Biomed. Anal.*, 2007, **45**, 38–46.
- 35 X. H. Fan, Y. Wang and Y. Y. Cheng, *J. Pharm. Biomed. Anal.*, 2006, **40**, 591–597.
- 36 Y. X. Sheng, L. Li, Q. Wang, H. Z. Guo and D. A. Guo, *J. Pharm. Biomed. Anal.*, 2005, **37**, 805–810.
- 37 J. B. Xie, W. Q. Wang, Y. Q. Zhang, Y. Bai and Q. Yang, *J. Pharm. Biomed. Anal.*, 2007, **45**, 450–455.
- 38 X. D. Wen, L. W. Qi, P. Li, K. D. Bao, X. W. Yan, L. Yi and C. Y. Li, *J. Chromatogr., B: Anal. Technol. Biomed. Life Sci.*, 2008, **865**, 99–105.
- 39 Y. H. Wang, Z. Chen, D. X. Xiang and Y. R. Ou, *Chin. Hosp. Pharm. J.*, 2006, **26**, 910–913.
- 40 S. Kanno, A. Shouji, R. Hirata, K. Asou and M. Ishikawa, *Life Sci.*, 2004, **75**, 353–365.
- 41 U. J. Jung, M. Lee, Y. B. Park, M. A. Kang and M. Choi, *Int. J. Biochem. Cell Biol.*, 2006, **38**, 1134–1145.
- 42 A. Balakrishnan and V. P. Menon, *Toxicology*, 2007, **238**, 90–98.